Search results
Author(s):
Francesco Pelliccia
Added:
8 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights…
View more
Author(s):
Gi-Byoung Nam
,
Min Soo Cho
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Prioritising Risk in CAD: A Patient-First Discussion
Video Series
Author(s):
Tobias Geisler
Added:
1 year ago
Author(s):
Armin Arbab-Zadeh
,
Michelle Graham
,
Hector M Garcia-Garcia
,
et al
Added:
4 months ago
Author(s):
Anna Meta Dyrvig Kristensen
Added:
2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Author(s):
Stephen Nicholls
Added:
2 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Author(s):
Frederick Welt
Added:
3 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Author(s):
Muthiah Vaduganathan
Added:
4 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more
Author(s):
James Burton
,
Clara Bonanad Lozano
,
Aaron Wong
,
et al
Start date:
Jul 02, 2025
.img-row:after {
content: "";
clear: both;
display: table;
}
.img-column {
float: left;
width: 50%;
padding: 5px;
}
@media screen and (max-width: 500px) {
.img-column {
width: 100%;
}
}
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)…
View more